Efficacy and evaluation on safety of beraprost sodium combined with immunosuppressor in treatment of primary nephrotic syndrome
10.13481/j.1671-587x.20180631
- Author:
Xueting WANG
1
Author Information
1. Department of Nephrology, China-Japan Union Hospital, Jilin University
- Publication Type:Journal Article
- Keywords:
Beraprost sodium;
Glucocorticoid;
Immunosuppressive;
Primary nephrotic syndrome
- From:
Journal of Jilin University(Medicine Edition)
2018;44(6):1291-1297
- CountryChina
- Language:Chinese
-
Abstract:
Objective; To explore the clinical efficacy and safety of beraprost sodium (BPS) combined with glucocorticoid (GC) and (or) immunosuppressive agents in the treatment of the patients with primary nephrotic syndrome (PNS), and to provide evidence for its application in the treatment of PNS. Methods; Eighty-six patients diagnosed as PNS definitely were selected. They were treated with GC and (or) immunosuppressive agents and were divided into BPS group (administrated with BPS, ra=42) and control group (administrated with dipyridamole or aspirin, n-) according to their willing to the acceptance of different anti-platelet treatment regimens. The relevant laboratory indexes of the patients in two groups before and after treatment were analyzed, and the effective rate, incidence of complications and drug adverse reactions of the patients in two groups were compared. Results; Comparedwith control group, the urinary protein levels of the patients in BPS group at the 1st and 6th months after treatment were significantly decresed (P<0. 05) and the serum albumin (ALB) levels of the patients in BPS group were significantly increased (P<0. 05); the levels of fibrinogen (FIB) and D-dimer (DD) of the patients in BPS group at the 3rd, 6th and 12th months after treatment were significantly decreased (P<0. 05 or P<0. 01). Compared with control group, the systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the patients in BPS group at the 1st month after treatment were decreased significantly (P<0. 05). The cholesterol (TC) level and total effective rate of the patients in BPS group at the 6th month after treatment were higher than those in control group (P<0. 05). Compared with control group, the incidence of elevation of blood pressure of the patients with normal basal blood pressure in BPS group was significantly decreased (P<0. 05); the incidence of headache and dizziness was significantly increased (P<0. 05). Conclusion: The safety of BPS combined with GC and (or) immunosuppressive agents in treating the PNS patients is higher and superior to the conventional antiplatelet agents.
